TIDES: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Sarah Boyce is an experienced life sciences industry leader who has built out and overseen divisions and global commercial operations for a range of innovative therapies including
Soliris®, Gleevec® and Tasigna®.
Ms. Boyce joined Akcea as a Board member and President in April 2018. Previously, she was the Chief Business Officer of Ionis Pharmaceuticals. In this role Ms. Boyce was responsible for leading investor relations and corporate communications, business development, alliance management, competitive intelligence and patient advocacy. She led the effort to establish a
global agreement with Ionis and Novartis to develop and commercialize AKCEA APOa‐LRX and AKCEA APOCIII‐LRX.
Ms. Boyce also served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. where she led the establishment and expansion of their
international pharmaceutical and consumer health businesses. Prior to Forest, she served as a global business leader at Alexion and Novartis. She received her B.S. degree in microbiology
from the University of Manchester, England.